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Introduction
At least 5% of familial Mediterranean fever(FMF) patients
do not respond to colchicine. We present our initial
treatment results with colchicine resistant patients.
Case Report
Methods
FMF resistance was defined as having ≥2 attacks in a
month and persistently high CRP and SAA levels during
the attack free period, in spite of adequate colchine dose.
All patients were homozygous or compound heterozygotes
for MEFV mutations. All continued colchicine tratment at
a mean dose of 0,04±0,01 mg/kg.
Results
Eleven patients with mean age of 12,7±7,7 years (median
14, ranging 1,5-23 years) were studied. These patients
were on colchicine treatment for a mean of 5,5±4,2 years.
In one patient initially etanercept was used however, this
was switched to anakinra since there was no repsonse to
anti TNF treatment. A total of 7 patiets were started ana-
kinra, however, 2 had local reactions and 2 was unrespon-
sive; they were switched to canakinumab treatment and
they all responded with normal acute phase reactants. At
this time a total of 8 patients are now being treated with
canakinumab with a mean duration of 10,8 ±6,8 months
and 3 patients with anakinra with a mean duration of 19,6
months. One patient who is on anakinra treatment has
HIDS mutation as well. There were no side effects.
Discussion
Anti IL1 treatment is beneficial in FMF patients who are
resistant to colchicine and can be used safely.
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